Breaking Drug News: Combination GLP-1s, Treatment for Kids, and Lp(a)
From Fat Science · · 47 min
This plays from the publisher's own server. We do not host a copy.
Description
What do new drug reports really mean for your treatment?
Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.
KEY TAKEAWAYS
- Understanding the difference between efficacy estimand and treatment policy estimand.
- Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.
- Semaglutide's effectiveness in children and its implications.
NOTABLE QUOTE
"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper
LINKS & RESOURCES
Learn more about Diabesity Foundations: learn.diabesityinstitute.org (https://diabesityinstitute.org)
Podcast Home:fatsciencepodcast.com (https://fatsciencepodcast.com/)
Cooper Center for Metabolism:coopermetabolic.com (https://coopermetabolic.com/)
Diabesity Institute: diabesityinstitute.org (https://diabesityinstitute.org)
Resources from Dr. Cooper:coopermetabolic.com/resources (https://coopermetabolic.com/resources)
Join Our Community:patreon.com/cw/FatSciencePodcast (https://patreon.com/cw/FatSciencePodcast)
Submit Your Question: questions@fatsciencepodcast.com (http://docs.google.com/questions@fatsciencepodcast.com) or dr.c@fatsciencepodcast.com (http://docs.google.com/dr.c@fatsciencepodcast.com)
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.